T-cell therapy for EBV-associated nasopharyngeal carcinoma: Preparative lymphodepleting chemotherapy does not improve clinical results

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 435-441

  Secondino, S ^a,b   Zecca, M ^b   Licitra, L ^c   Gurrado, A ^b   Schiavetto, I ^a   Bossi, P ^c   Locati, L ^c   Schiavo, R ^a   Basso, S ^b   Baldanti, F ^b   Maccario, R ^b   Locatelli, F ^b,d   Siena, S ^a   Pedrazzoli, P ^a,b   Comoli, P ^b  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Cell therapy; Cytotoxic T lymphocytes; Epstein Barr virus; Lymphodepletion; Nasopharyngeal carcinoma

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CYCLOPHOSPHAMIDE; FLUDARABINE; RECOMBINANT INTERLEUKIN 2;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANEMIA; ARTICLE; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CELL EXPANSION; CELL SPECIFICITY; CELL THERAPY; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DRUG FEVER; EPSTEIN BARR VIRUS INFECTION; FATIGUE; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LYMPHODEPLETING CHEMOTHERAPY; MALE; NASOPHARYNX CARCINOMA; NAUSEA; NEUTROPENIA; ORBIT EDEMA; ORBIT INFLAMMATION; PATIENT SAFETY; PRIORITY JOURNAL; SWELLING; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; TREMOR; VISUAL FIELD DEFECT;

ADULT; AGED; DISEASE PROGRESSION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TISSUE THERAPY; YOUNG ADULT;

EID: 84856341038     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr134     Document Type: Article

References (36)

1. Chan ATC, Teo PML, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol 2002; 13: 1007-1015.
2. Chan ATC, Felip E. ESMO Guidelines Working Group. Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19: ii81-ii82.
3. Langendijk JA, Leemans CR, Buter J et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 2004; 22: 4604-4612.
4. Dimery IW, Peters LJ, Goepfert H et al. Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma. J Clin Oncol 1993; 11: 1919-1928.
5. Johnson FM, Garden A, Palmer JL et al. A phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. Cancer 2004; 100: 991-998.
6. Au E, Ang PT. A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol 1994; 5: 87-89.
7. Taamma A, Fandi A, Azli N et al. Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer 1999; 86: 1101-1108.
8. Zhang L, Zhang Y, Huang PY et al. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy. Cancer Chemother Pharmacol 2008; 61: 33-38.
9. Leong SS, Wee J, Tay MH et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a phase II trial using a triplet combination. Cancer 2005; 103: 569-575.
10. Chua DTT, Kwong DLW, Sham JST et al. A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy. Eur J Cancer 2000; 36: 736-741.
11. Fandi A, Bachouchi M, Azli N et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol 2000; 18: 1324-1330.
12. Rickinson AB, Kieff E. Epstein-Barr virus. In Fields BN, Knipe DM (eds), Virology. New York: Raven Press 1996; 2397-2446.
13. Rooney CM, Smith CA, Ng CY et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9.
14. Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549.
15. Comoli P, Maccario R, Locatelli F et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBVspecific T cells. Am J Transplant 2005; 5: 1415-1422.
16. Comoli P, Rooney CM. Treatment of Epstein-Barr virus infections. In Tselis A, Jenson HB (eds), Epstein-Barr Virus. New York: Taylor and Francis 2006; 353-374.
17. Straathof KC, Bollard CM, Popat U et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005; 105: 1898-1904.
18. Comoli P, Pedrazzoli P, Maccario R et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T-lymphocytes. J Clin Oncol 2005; 23: 8942-8949.
19. Comoli P, De Palma R, Siena S et al. Adoptive transfer of allogeneic EBV-specific cytotoxic T cells with in vitro antitumor activity boosts LMP-2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol 2004; 15: 113-117.
20. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
21. Baldanti F, Gatti M, Furione M et al. Kinetics of Epstein-Barr virus DNA load in different blood compartments of pediatric recipients of T-cell depleted HLAhaploidentical stem cell transplantation. J Clin Microbiol 2008; 46: 3672-3677.
22. Lin JC, Wang WY, Chen KY et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350: 2461-2470.
23. Rosenberg SA, Restifo NP, Yang JC et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8: 299-308.
24. Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-2357.
25. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949.
26. Viguier M, Lemai{dotless}̂ tre F, Verola O et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004; 173: 1444-1453.
27. Mantovani A, Romero P, Palucka AK et al. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008; 371: 771-783.
28. Knutson KL, Wagner W, Disis ML. Adoptive T cell therapy of solid cancers. Cancer Immunol Immunother 2006; 55: 96-103.
29. Yee C, Thompson JA, Byrd D et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002; 99: 16168-16173.
30. Hunder NN, Wallen H, Cao J et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698-2703.
31. Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26: 5233-5239.
32. Louis CU, Straathof K, Bollard CM et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 2009; 113: 2442-2450.
33. Ranieri E, Herr W, Gambotto A et al. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J Virol 1999; 73: 10416-10425.
34. Gahn B, Siller-Lopez F, Pirooz AD et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to the LMP2A-antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer 2001; 93: 706-713.
35. Gottschalk S, Edwards OL, Sili U et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBVassociated malignancies. Blood 2003; 101: 1905-1912.
36. Bollard CM, Gottschalk S, Leen AM et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007; 110: 2838-2845.